Home
Clinical Trials
Study of Brain Imaging With N...

Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome

Last Updated: 2019-04-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

500 participants

Study Classification

INTERVENTIONAL

Study Start Date

1992-09-30

Study Completion Date

2005-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study assesses dopamine transporter density using single photon emission computed tomography (SPECT) brain imaging with an investigational radiopharmaceutical, \[123I\]ß-CIT, in research participants with Parkinson's disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease

NCT00117819

Parkinsonian Syndrome

COMPLETED PHASE2

Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression

NCT00134784

Parkinson Disease

COMPLETED PHASE2

Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease

NCT00404170

Parkinson Disease

COMPLETED PHASE2

PharmacoMRI of Parkinson Disease

NCT01528592

Parkinson's Disease

COMPLETED NA

Trodat 1 SPECT and Dopamine Polymorphism

NCT01381302

Parkinson Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The brain imaging is conducted at the Institute for Neurodegenerative Disorders in New Haven, Connecticut. The imaging procedure occurs over a two day period.

After a screening visit, including review of the potential subject's neurological history and a thorough neurologic exam, subjects are injected with \[123I\]ß CIT, an investigational radioactive material that localizes in the brain.

Twenty-four hours later study participants return to the Institute for Neurodegenerative Disorders where an investigational scanning procedure is used to obtain SPECT (single photon emission computed tomography) images of the brain.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease Parkinsonian Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[123I]ß-CIT and SPECT imaging

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least 21 years of age
* Normal screening laboratory studies
* At least two of the following: resting tremor, cogwheel rigidity, bradykinesia, and postural reflex impairment